New FDA-approved medical treatments can be transformative for patients and families, often providing them with more years to live and an enhanced quality of life. 1 Delivering timely, high-quality ...
A tool combining CV risk score (CVRS) and coronary artery calcium score (CACS) facilitates stratification of patients with COPD at risk for MACE.
Discover how chronic respiratory failure increases heart disease risk in COPD patients. Learn why early cardiovascular ...
One patient could only walk 15 to 20 steps before needing to get back on her oxygen, making it difficult to find motivation to engage in daily activities. Another patient struggled with severe ...
A symposium at the 2023 American Thoracic Society International Conference highlighted common comorbidities that warrant consideration in patients who present with chronic obstructive pulmonary ...
In Tarrant County, patients with severe chronic obstructive pulmonary disease, COPD, now have access to a procedure that can lessen airflow blockage and improve their quality of life. KERA’s Sam Baker ...
It seems patient satisfaction is low when it comes to their chronic obstructive pulmonary disease (COPD) treatment, according to a recent report out from consultancy Phreesia Life Sciences. When ...
Patients with chronic obstructive pulmonary disease (COPD) are more likely to die within a year of undergoing elective surgery and to incur higher healthcare costs than similar patients without COPD, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In those with and those without emphysema, patients ...
CHICAGO — Hospital volume affected the length of stay for patients with COPD who elect to have endobronchial valve placement, with some association with costs as well, according to an abstract ...
Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...